Funding for this research was provided by:
Janssen Research and Development
Received: 22 December 2018
Accepted: 25 July 2019
First Online: 20 August 2019
Ethics approval and consent to participate
: The GO-FURTHER trial was conducted in accordance with Good Clinical Practice and the Declaration of Helsinki. The protocol was approved by the Institutional Review Board or ethics committee at each site. All patients gave written informed consent before any study-related procedures were performed.
: Not applicable.
: JT has received consulting and speaker fees and research support from AbbVie, Amgen, Janssen, Lilly, and Pfizer. AT has received consulting and speaker fees and research support from AbbVie, Janssen, Lilly, Medac, Novartis, Pfizer, and Regeneron. SK, RJD, SX, and ECH are or were employees of Janssen Research & Development, LLC. at the time this work was performed and own stock in Johnson & Johnson, of which Janssen Research & Development, LLC. is a wholly-owned subsidiary.